Latest News

STAT Plus: Sage’s CEO reflects on progress treating postpartum depression and what Biogen’s big Alzheimer’s failure means

Postpartum depression is the most common complication of childbirth. Yet it’s a condition that often goes untreated because mothers fear being stigmatized if they report symptoms.

On Tuesday the Food and Drug Administration approved brexanolone, the first drug specifically targeted to treat postpartum depression. To be marketed as Zulresso, it’s the first drug developed by and approved from Sage Therapeutics of  Cambridge, Mass. Jeff Jonas, Sage’s CEO, recently chatted with STAT about the drug, its price, and how it’s administered. He also shared some thoughts on Biogen and the failure of its biggest hope for an Alzheimer’s drug.

Continue to STAT Plus to read the full story…

Source link

Related posts

Study examines impact of Medicaid expansion on hiring attempts in substance use treatment workforce


New approach shows important role of microRNAs in papillomavirus life cycle


Can kidney transplants with injured donor kidneys still be successful?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World